AURORA

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
FDA, Research, IRON, Glycine, Erythropoiesis, Food, EPP, PV, Sodium- and chloride-dependent glycine transporter 1, G&A, AURORA, Iron, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ruxolitinib, Light, Porphyria, Inflammation, Poster, Sunlight, Society, ASH, Development, Photosensitivity, Hematology, Quality of life, Phase 10, Anemia, PPIX, Safety, MF, XLP, Pain, Patient, Administration, Polycythemia, Rare-earth element, Pharmaceutical industry, Vaccine, Disc

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $370.5 million as of September 30, 2023, which are expected to fund our operational plans well into 2026.
  • Research and Development Expenses: R&D expenses were $14.4 million for the quarter ended September 30, 2023, as compared to $7.9 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: G&A expenses were $4.5 million for the quarter ended September 30, 2023, as compared to $2.6 million for the same period in 2022.
  • Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to $16.2 million for the third quarter of 2022.

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Health, Science, Research, Clinical Trials, Patient, Lupus nephritis, Week, American College, CNI, EGFR, Human, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., TAC, AURORA, Safety, University of California, CSA, VCS, Lupus, Society, Mouse, Acute kidney injury, Ciclosporin, Division, Clinical trial, Efficacy, Physiology, Biopsy, MMF, University, Tacrolimus, Glucocorticoid, ACR, Conditional sentence, Proteinuria, Lithium toxicity, Pharmaceutical industry, Rheumatology, Black, ALMS, Aurinia, Medicine, UPCR, LN

Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.

Key Points: 
  • Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.
  • In AURORA 1, patients received LUPKYNIS® 23.7 mg BID in combination with MMF (target dose 2 g/day) and oral glucocorticoids (starting dose of 25 mg/day tapered to 2.5 mg/day by Week 16).
  • The data showed an improved safety profile over the first six months of treatment with LUPKYNIS® in combination with low-dose glucocorticoids and lower-dose MMF without compromising efficacy.
  • Additional data assessed the disposition of cyclosporine (CSA), tacrolimus (TAC), and voclosporin (VCS) in mouse kidneys relative to its systemic drug exposure.

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

Retrieved on: 
Thursday, November 2, 2023
IRON, EPP, AURORA, Ruxolitinib, Society, Sunlight, ASH, Interim, Protoporphyrin IX, Anemia, PPIX, Exposition, Pain, Patient, Pharmaceutical industry, Disc

“We look forward to presenting updated interim data from all patients enrolled in the BEACON study at the upcoming ASH meeting, as well as preliminary clinical data from initial cohorts of both DISC-0974 anemia studies.” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.

Key Points: 
  • “We look forward to presenting updated interim data from all patients enrolled in the BEACON study at the upcoming ASH meeting, as well as preliminary clinical data from initial cohorts of both DISC-0974 anemia studies.” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
  • “In addition, we’re pleased to announce the full enrollment of both the BEACON and AURORA studies of bitopertin in patients with EPP.
  • The full abstracts are now available through the ASH conference website.
  • Please register for management’s webcast on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/).

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

Retrieved on: 
Thursday, November 2, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Patient, Lupus nephritis, National Institutes of Health, CNI, EGFR, Kidney failure, AURORA, Safety, Lupus, Kidney, ALMS, Society, Acute kidney injury, Clinical trial, ASN, MMF, NIH, Histology, Glucocorticoid, UPCR, Conditional sentence, Bangladesh Technical Education Board, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Ohio State University Wexner Medical Center, Proteinuria, Toxic leukoencephalopathy, Pharmaceutical industry, Black, Aurinia, LN

Results from an analysis of kidney biopsy samples collected from patients participating in the AURORA Clinical Program were presented in an oral session.

Key Points: 
  • Results from an analysis of kidney biopsy samples collected from patients participating in the AURORA Clinical Program were presented in an oral session.
  • Activity scores for both arms improved to a similar degree, while the chronicity scores remained stable in both arms.
  • “The results presented at ASN this week demonstrate important clinical and mechanistic findings associated with LUPKYNISⓇ treatment.
  • Following is the complete guide to Aurinia’s presentations at ASN 2023:
    Title: Comparison of dual-immunosuppressive therapy and a voclosporin-based, triple-immunosuppressive regimen for lupus nephritis: a propensity analysis of ALMS and AURORA 1 studies

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, SLE, PSF, FDA, Insurance, American College, EGFR, U.S.–Canada Team Tournament (Go), Conversation, SG, EDGAR, SEDAR, American Society of Nephrology, AURORA, Nephrology, Lupus, Persistent environment, EC, Glomerular filtration rate, R, Society, Arthritis & Rheumatology, Bank statement, Growth, Risk, Marketing, Webcast, Analysis, Healthcare Improvement Scotland, American College of Rheumatology, Safety, LN, Investment, Management, Patient, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Rheumatology, Cryptocurrency, Pharmaceutical industry, Rare-earth element, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.
  • Total net revenue was $54.5 million for the three months ended September 30, 2023 and $55.8 million for the same period in 2022.
  • Financial Results for the Three and Nine Months Ended September 30, 2023
    Total net revenue was $54.5 million and $55.8 million for the three months ended September 30, 2023 and September 30, 2022, respectively.
  • Aurinia will host a conference call and webcast to discuss the quarter ended September 30, 2023 financial results today, Thursday, November 2, 2023 at 8:30 a.m.

Behavioral Health Study Uncovers Remarkable Results: Measurement-Based Care with Owl Reduces Behavioral Health Adverse Events, Slashes Costs for Colorado Medicaid Plan

Retrieved on: 
Wednesday, October 25, 2023
Aurora, Patient, Public sector, AURORA, HEDIS, Aurora Mental Health & Recovery, Owl, MBC, Health, Partnership, Medicaid, Nursing, Hospital, Health insurance, Pharmaceutical industry, Management

AURORA, Colo., Oct. 25, 2023 /PRNewswire/ -- Owl, a behavioral health technology company, today announced the results of a measurement-based care (MBC) impact study in collaboration with Colorado Access, the largest public sector health plan in Colorado, and Aurora Mental Health & Recovery, a certified community behavioral health clinic.

Key Points: 
  • AURORA, Colo., Oct. 25, 2023 /PRNewswire/ -- Owl , a behavioral health technology company, today announced the results of a measurement-based care (MBC) impact study in collaboration with Colorado Access , the largest public sector health plan in Colorado, and Aurora Mental Health & Recovery , a certified community behavioral health clinic.
  • Behavioral health study shows the power of MBC in improving patient care and outcomes while delivering cost savings.
  • "The results from this measurement-based care impact study are astounding," said Lindsay Cowee, senior director of behavioral health network performance at Colorado Access.
  • Aurora Mental Health & Recovery is a certified community behavioral health clinic on a mission to elevate the standards of behavioral health care.

BigBear.ai Broadens its Work with the U.S. Air Force, Leveraging Advanced AI to Assist in Military Planning

Retrieved on: 
Monday, October 16, 2023
NYSE, Air Force Research Laboratory, CRAE, COA, AFRL, AURORA, United States Department of Defense, BBAI, Oil

To date, BigBear.ai has collaborated with AFRL to accelerate the military planning process.

Key Points: 
  • To date, BigBear.ai has collaborated with AFRL to accelerate the military planning process.
  • “We are honored to be a part of the United States Military's ongoing efforts to modernize military planning and preparedness,” said Mandy Long, CEO of BigBear.ai.
  • “Our planning tools will be augmented specifically to address contested logistics challenges, resulting in dramatic improvements to risk-informed planning.
  • BigBear.ai’s work on Project AURORA:
    Aims to condense the conventional two-year planning timeframe, presenting comprehensive, resource-backed operational plans in under a month.

Magna Introduces Industry-First, 100% Melt Recyclable Foam and Trim Seating Solutions

Retrieved on: 
Wednesday, October 11, 2023
Foam, Trim, AURORA, Carbon, Magna, PET, Wood-plastic composite

Magna’s new EcoSphere product family is comprised of sustainable trim materials, trim padding, structures and foam.

Key Points: 
  • Magna’s new EcoSphere product family is comprised of sustainable trim materials, trim padding, structures and foam.
  • The product family leverages Magna's expertise in the integration of foam chemistry, trim manufacturing, craftsmanship and tooling to develop a seamless and affordable solution.
  • In addition, the 100% Melt Recyclable Foam and Trim technology ensures that the look and feel of the seating materials remain consistent with industry standards, while significantly reducing the environmental impact.
  • Our technology offers automakers a game-changing opportunity to enhance sustainability without compromising on comfort, quality or performance.”
    Magna EcoSphere Trim Foundation is an essential part of the 100% Melt Recyclable Foam and Trim technology.

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)

Retrieved on: 
Friday, October 13, 2023
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Efficacy, ACR, Abstract, Daubert v. Merrell Dow Pharmaceuticals, Inc., American College, Nephrology, Therapy, Society, Safety, Lupus nephritis, Autoimmune disease, ASN, Rheumatology, AURORA, Patient, ALMS, Lupus, American Society of Nephrology, SLE, Pharmaceutical industry, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from 14 studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2-5 in Philadelphia, Pennsylvania and at the 2023 American College of Rheumatology Convergence (ACR), taking place November 10-15 in San Diego, California.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from 14 studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2-5 in Philadelphia, Pennsylvania and at the 2023 American College of Rheumatology Convergence (ACR), taking place November 10-15 in San Diego, California.
  • Led by several leading experts in nephrology and rheumatology, these presentations reinforce the long-term safety and efficacy profile of LUPKYNIS® for the treatment of adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).
  • The robust set of data demonstrates Aurinia’s deep commitment to sustained research in autoimmune diseases, including lupus.
  • The abstracts for ASN Kidney Week 2023 are listed below and available online at: https://www.asn-online.org/education/kidneyweek/2023/program-search-abst...
    The abstracts for ACR 2023 are listed below and available online at: https://acrabstracts.org/
    Aurinia will issue full data press releases at the time of the meetings.

Bloomhaven Honored with Prestigious Design Award for Transformative Hospital Renovation

Retrieved on: 
Saturday, October 14, 2023
Aurora, Health, Multimedia, American Institute of Architects, Honor Award, Asbestos, AIA, Happiness, Education, AURORA, Crime, American Institute, Interior design, Architect

AURORA, Ill., Oct. 14, 2023 /PRNewswire-PRWeb/ -- Kluber Architects + Engineers is proud to announce that they have received an American Institute of Architects (AIA) Award from the Northeast Illinois branch for the renovation of the Old Copley Hospital in Aurora.

Key Points: 
  • AURORA, Ill., Oct. 14, 2023 /PRNewswire-PRWeb/ -- Kluber Architects + Engineers is proud to announce that they have received an American Institute of Architects (AIA) Award from the Northeast Illinois branch for the renovation of the Old Copley Hospital in Aurora.
  • The American Institute of Architects' "Preservation/Renovation" Honor Award recognizes firms who have designed for the renovation of facilities that honor their community, and this accolade highlights the firm's commitment to innovation and revitalization.
  • Bloomhaven has become a hub for health, wellness, and happiness, providing essential services and education to people of all backgrounds.
  • From cutting edge public works facilities to complicated renovation projects like Bloomhaven, their diverse experience has led to several award-winning projects.